Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056638 · ClinicalTrials.gov registry record · Phase 3
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
A Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
NCT03056638: Clinical Trial Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03056638 is a Phase 3 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03056638, a Phase 3 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
Study Summary
Stereotactic body radiation therapy (SBRT) is a very precise form of radiation therapy that allows the physician to deliver more radiation dose in a single session. Because of this, the number of radiation sessions can be reduced from the typical 45-48 sessions, as in conventional daily session radiation, to 5 sessions given every other day over a week and a half. Giving the radiation at a higher dose during each treatment may be more effective in killing the prostate cancer cells than the standard way of using external radiation therapy where a small amount of radiation is given over many sessions. Androgen Deprivation Therapy (ADT) or hormonal therapy is one of the methods to treat intermediate risk prostate cancer. This therapy works by reducing the level of testosterone and stopping them from affecting your cancer. The ADT used in this study is known as Degarelix. Degarelix is an approved medication that reduces the body's production of testosterone; this medication is usually given to all men with intermediate risk prostate cancer getting external radiation. This study is a randomized study to find out whether combining stereotactic (also known as precision) radiation to the prostate cancer combined with a short course of Degarelix will result in a greater likelihood of killing the cancer in the prostate compared to stereotactic radiation therapy given alone. It has been shown that the combination of radiation with medications that interfere with testosterone production and its effects makes prostate cancer cells more sensitive to the radiation.
Interventions
- DRUG Degarelix
- RADIATION stereotactic body radiosurgery (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-03-28 |
| Est. Completion | 2023-08-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03056638
The ClinicalTrials.gov registry entry for NCT03056638 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Degarelix is the first listed.
NCT03056638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03056638 about?
NCT03056638 is a clinical study titled "Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer". Stereotactic body radiation therapy (SBRT) is a very precise form of radiation therapy that allows the physician to deliver more radiation dose in a single session. Because of this, the number of radiation sessions can be reduced from the typical 45-48 sessions, as in conventional daily session radi...
What is the current status of trial NCT03056638?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2017-03-28. Estimated completion is 2023-08-16.
What interventions are being tested in trial NCT03056638?
The interventions under investigation include: Degarelix (DRUG), stereotactic body radiosurgery (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT03056638?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.